Sai Parenteral's IPO
Historical offer record. This offer is closed for applications. Prices and subscriptions describe the past offer; GMP observations are unofficial past records, not current quotes or listing predictions.
Data provider: FinAPI. This is a third-party summary, not an official prospectus. Read our data limitations and editorial policy.
No GMP observations are available for this historical offer record. No premium or listing-gain estimate is shown.
Price band
₹372 – ₹392
Lot size
38 shares
Offer application amount
₹14,896
Issue size
₹409 Cr
Historical offer amount for 1 lot at the upper issue price. Confirm the lot size and application terms in the issuer prospectus.
Reported IPO schedule
| Open date | 24 Mar 2026 |
| Close date | 27 Mar 2026 |
| Allotment finalisation | 30 Mar 2026 |
| Refund initiation | 1 Apr 2026 |
| Shares credited to demat | 1 Apr 2026 |
| Reported listing date | 2 Apr 2026 |
Issue size
About Sai Parenteral's
Sai Parenteral’s Ltd., founded in 2001, is one of the leading pharmaceutical companies focused on R&D and manufacturing of pharmaceutical products. The firm operates in 2 main business areas: makes and sells its own branded medicines, and also manufactures medicines for other companies internationally. Its product offerings include a wide range of medicines for various health conditions, like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals, and supplements (VMS), analgesics, and dermatology.
Company summary supplied by FinAPI. Read the prospectus for the issuer's disclosures and audited financials.
Use of proceeds
| Capacity expansion and upgradation of manufacturing facilities | ₹110.80 |
| Establishment of a new R&D Centre; | ₹18.02 |
| Repayment / prepayment of certain outstanding borrowings | ₹20.00 |
| Working capital requirements | ₹33.00 |
| Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | ₹36.00 |
| General corporate purposes | ₹- |
Offer documents and primary references
Read the issuer's offer document and any corrigenda for the full disclosures. A third-party details page is a summary; SEBI filing access does not imply an endorsement of the offer or this website.
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.